Dolly Parton Serves Up Sweetness with Krispy Kreme Collaboration 
Converse Faces Job Cuts as Nike Aims for $2 Billion in Cost Savings 
BYD Launches Shark Hybrid Pickup in Mexico, Eyes New Factory Amid US Tariff Hike 
Aldi, Hy-Vee Recall Cream Cheese Products Over Potential Salmonella Contamination 
Semaglutide's Benefits Beyond Weight Loss: New Insights from the SELECT Trial 
Green industry yes, conservation no: a budget for people, not for nature 
McDonald's Faces Backlash Over $5 Meal Deal: Customers Call It 'Skimpy' 
Burger King Introduces Mozzarella Fries: A New Spin on an Old Favorite 
McDonald's Philippines Launches 'Ride the Arches' for Cyclists 
Nike vs. Adidas: Anthony Edwards’ and Wembanyama’s Sneakers Soar in Popularity 
From Burger King to McDonald’s: Fast-Food Prices Surge Dramatically in Recent Years 
Shein's Potential London IPO Could Revitalize LSE Amid Geopolitical Tensions 
EMERYVILLE, Calif., March 04, 2016 -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing therapies for the treatment of central nervous system (CNS) disorders, today announced that it will report its financial results for the fourth quarter and full-year ended December 31, 2015 after the market close, and will host a corporate update conference call and webcast on Thursday, March 10th at 4:30 PM Eastern Time.
| Thursday, March 10th @ 4:30 PM Eastern Time/1:30 PM Pacific Time | |
| Toll Free: | 888-337-8198 |
| International: | 719-325-2308 |
| Conference ID: | 5464024 |
| Webcast: | http://public.viavid.com/index.php?id=118497 |
| Replays, available through March 24, 2016: | |
| Domestic: | 877-870-5176 |
| International: | 858-384-5517 |
| Conference ID: | 5464024 |
About Zogenix
Zogenix, Inc. (NASDAQ:ZGNX) is an innovative pharmaceutical company committed to providing unique therapeutic solutions for people living with rare and burdensome disease conditions. Our focused strategy centers on advancing late-stage, high-value products for CNS disorders that will significantly improve outcomes for patients and physicians.
For more information, visit www.zogenix.com.
CONTACT: Investors: Andrew McDonald Founding Partner, LifeSci Advisors LLC 646-597-6987 | [email protected]
